Patents by Inventor Kameshwari AMBATI
Kameshwari AMBATI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11717520Abstract: The present disclosure relates to compounds and compositions that inhibit the NLRP3 inflammasome, for example, or a pharmaceutically acceptable salt thereof. Also disclosed are methods for treating, and in particular methods for treating macular degeneration, e.g., dry age-related macular degeneration (AMD) and wet AMD, Alzheimer's disease, multiple sclerosis, and Parkinson's disease, using compounds and compositions that inhibit the NLRP3 inflammasome.Type: GrantFiled: March 2, 2021Date of Patent: August 8, 2023Assignee: University of Kentucky Research FoundationInventors: Jayakrishna Ambati, Benjamin Fowler, Kameshwari Ambati
-
Publication number: 20230172962Abstract: Methods for treating and/or inhibiting progression of diseases, conditions, and/or disorders. In some embodiments, the methods include administering to as subject in need thereof a composition that includes a nucleoside reverse transcriptase inhibitor (NRTIs), an NRTI metabolite, an NRTI analog, a pharmaceutically acceptable salt and/or metabolite thereof, a prodrug of an NRTI, or any combination thereof. Also provided are methods for inhibiting development of macular degeneration in subjects; methods for inhibiting development and/or progression of viral infection and/or a disease, condition, disorder, and/or symptom associated therewith in a subject in need thereof; methods for inhibiting development and/or progression of acute respiratory distress syndrome in subjects; methods for inhibiting development and/or progression of cytokine storm syndrome in subjects; methods for inhibiting development and/or progression of fibrosis in subjects, and compositions for use in the presently disclosed methods.Type: ApplicationFiled: March 19, 2021Publication date: June 8, 2023Applicant: University of Virginia Patent FoundationInventors: Jayakrishna Ambati, Kameshwari Ambati
-
Publication number: 20220280543Abstract: Provided are methods for treating and/or preventing diseases, disorders, and/or conditions associated with NLR family CARD domain containing 4 (NLRC4) inflammasome biological activities. In some embodiments, the method include administering to a subject in need thereof a composition that includes a nucleoside reverse transcriptase inhibitor (NRTI). Also provided are methods for inhibiting NLRC4-induced caspase-1 activation in cells, methods for inhibiting NLRC4-induced IL-I? release from cells, methods for inhibiting Alu-induced retinal pigmented cell (RPE) degeneration in subjects, and compositions for use in the presently disclosed methods.Type: ApplicationFiled: August 24, 2020Publication date: September 8, 2022Applicant: University of Virginia Patent FoundationInventors: Jayakrishna Ambati, Shao-bin Wang, Kameshwari Ambati
-
Patent number: 11219623Abstract: The present disclosure relates to modified nucleoside reverse transcriptase inhibitors (NRTIs), such as and compositions thereof, as well as methods useful for treating retinal damage and/or retinal degradation/retinal degeneration, for inhibiting inflammasome activation by Alu RNA associated with a cell, for reducing ATP-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell.Type: GrantFiled: March 22, 2019Date of Patent: January 11, 2022Assignee: University of Kentucky Research FoundationInventors: Jayakrishna Ambati, Benjamin Fowler, Kameshwari Ambati
-
Publication number: 20210348164Abstract: Provided are method for treating age-related macular degeneration (AGE), and/or preventing the occurrence or progression thereof in a subject in need thereof. In some embodiments, the methods include administering to the subject in need thereof a composition that has an effective amount of an inhibitor of reverse transcriptase (RTase) activity. Also provided are methods for protecting retinal pigmented epithelium (RPE) cells, retinal photoreceptor cells, and/or choroidal cells; methods for treating geographic atrophy of the eye, and/or for preventing occurrence or progression thereof; and pharmaceutical compositions for treating AGE and/or GA and/or for preventing the occurrence or progression thereof; and/or for protecting RPE cells, retinal photoreceptor cells, and/or choroidal cells.Type: ApplicationFiled: October 9, 2019Publication date: November 11, 2021Applicants: University of Virginia Patent Foundation, University of Kentucky Research FoundationInventors: Jayakrishna Ambati, Bradley David Unti Gelfand, Nagaraj Kerur, Shinichi Fukuda, Kameshwari Ambati, Benjamin Fowler
-
Publication number: 20210228578Abstract: The present disclosure relates to compounds, compositions, and methods useful for treating retinal damage and/or retinal degradation/retinal degeneration, for inhibiting inflammasome activation by Alu RNA associated with a cell, for reducing ATP-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell. The present disclosure further relates to compounds, compositions, and methods for use in protecting an RPE cell and/or for treating, including prophylactic and therapeutic treatment, of conditions associated with retinal damage and/or degradation including, but not limited to, dry age related macular degeneration (AMD) and wet AMD, Alzheimer disease, various forms of arthritis, atherosclerosis, diabetes mellitus, chronic obstructive pulmonary disease, inflammatory bowel disease, and Duchenne muscular dystrophy.Type: ApplicationFiled: March 2, 2021Publication date: July 29, 2021Inventors: Jayakrishna Ambati, Benjamin Fowler, Kameshwari Ambati
-
Publication number: 20210228579Abstract: The present disclosure relates to compounds, compositions, and methods useful for treating retinal damage and/or retinal degradation/retinal degeneration, for inhibiting inflammasome activation by Alu RNA associated with a cell, for reducing ATP-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell. The present disclosure further relates to compounds, compositions, and methods for use in protecting an RPE cell and/or for treating, including prophylactic and therapeutic treatment, of conditions associated with retinal damage and/or degradation including, but not limited to, dry age related macular degeneration (AMD) and wet AMD, Alzheimer disease, various forms of arthritis, atherosclerosis, diabetes mellitus, chronic obstructive pulmonary disease, inflammatory bowel disease, and Duchenne muscular dystrophy.Type: ApplicationFiled: March 2, 2021Publication date: July 29, 2021Inventors: Jayakrishna Ambati, Benjamin Fowler, Kameshwari Ambati
-
Publication number: 20210220359Abstract: The present disclosure relates to compounds, compositions, and methods useful for treating retinal damage and/or retinal degradation/retinal degeneration, for inhibiting inflammasome activation by Alu RNA associated with a cell, for reducing ATP-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell. The present disclosure further relates to compounds, compositions, and methods for use in protecting an RPE cell and/or for treating, including prophylactic and therapeutic treatment, of conditions associated with retinal damage and/or degradation including, but not limited to, dry age related macular degeneration (AMD) and wet AMD, Alzheimer disease, various forms of arthritis, atherosclerosis, diabetes mellitus, chronic obstructive pulmonary disease, inflammatory bowel disease, and Duchenne muscular dystrophy.Type: ApplicationFiled: March 2, 2021Publication date: July 22, 2021Inventors: Jayakrishna Ambati, Benjamin Fowler, Kameshwari Ambati
-
Publication number: 20190262341Abstract: The present disclosure relates to compounds, compositions, and methods useful for treating retinal damage and/or retinal degradation/retinal degeneration, for inhibiting inflammasome activation by Alu RNA associated with a cell, for reducing ATP-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell. The present disclosure further relates to compounds, compositions, and methods for use in protecting an RPE cell and/or for treating, including prophylactic and therapeutic treatment, of conditions associated with retinal damage and/or degradation including, but not limited to, dry age related macular degeneration (AMD) and wet AMD, Alzheimer disease, various forms of arthritis, atherosclerosis, diabetes mellitus, chronic obstructive pulmonary disease, inflammatory bowel disease, and Duchenne muscular dystrophy.Type: ApplicationFiled: March 22, 2019Publication date: August 29, 2019Inventors: Jayakrishna Ambati, Benjamin Fowler, Kameshwari Ambati
-
Patent number: 10294220Abstract: The present disclosure relates to nucleosides, such as compositions, and methods useful for treating retinal damage and/or retinal degradation/retinal degeneration, for inhibiting inflammasome activation by Alu RNA associated with a cell, for reducing ATP-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell. The present disclosure further relates to nucleosides, such as compositions, and methods for use in protecting an RPE cell and/or for treating, including prophylactic and therapeutic treatment, of conditions associated with retinal damage and/or degradation including, but not limited to, dry age related macular degeneration (AMD) and wet AMD, Alzheimer disease, various forms of arthritis, atherosclerosis, diabetes mellitus, chronic obstructive pulmonary disease, inflammatory bowel disease, and Duchenne muscular dystrophy.Type: GrantFiled: February 26, 2016Date of Patent: May 21, 2019Assignee: University of Kentucky Research FoundationInventors: Jayakrishna Ambati, Benjamin Fowler, Kameshwari Ambati
-
Publication number: 20180044327Abstract: The present disclosure relates to compounds, compositions, and methods useful for treating retinal damage and/or retinal degradation/retinal degeneration, for inhibiting inflammasome activation by Alu RNA associated with a cell, for reducing ATP-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell. The present disclosure further relates to compounds, compositions, and methods for use in protecting an RPE cell and/or for treating, including prophylactic and therapeutic treatment, of conditions associated with retinal damage and/or degradation including, but not limited to, dry age related macular degeneration (AMD) and wet AMD, Alzheimer disease, various forms of arthritis, atherosclerosis, diabetes mellitus, chronic obstructive pulmonary disease, inflammatory bowel disease, and Duchenne muscular dystrophy.Type: ApplicationFiled: February 26, 2016Publication date: February 15, 2018Inventors: Jayakrishna AMBATI, Benjamin FOWLER, Kameshwari AMBATI